PMID- 21323523
OWN - NLM
STAT- MEDLINE
DCOM- 20110621
LR  - 20191210
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 3
DP  - 2011 Mar
TI  - Prospective study of clinical and biological prognostic factors at diagnosis in 
      patients with early stage B-cell chronic lymphocytic leukemia.
PG  - 429-35
LID - 10.3109/10428194.2010.545463 [doi]
AB  - Retrospective series have reported many clinical and biological significant 
      prognostic factors in chronic lymphocytic leukemia (CLL). We describe a 
      prospective cohort of 135 patients with CLL homogeneously studied at diagnosis 
      for prognostic factors. Biological variables analyzed were CD38 and ZAP-70 
      expression, fluorescence in situ hybridization (FISH) for 13q-, +12, 11q-, and 
      17p-, and conventional cytogenetics. Univariate and multivariate analysis for 
      progression-free survival (PFS) were performed in patients with early stage (Rai 
      0-1) CLL. CD38 was positive in 42 (31.6%) patients and ZAP-70 in 47 (35.9%). The 
      most frequent FISH finding was isolated 13q- in 50 (38.5%) patients, and 
      17p- -was found in 11 (8.4%). Among 135 patients, 114 (84.4%) were Rai 0-1 at 
      diagnosis and 39 (28.9%) presented adenopathies. With a median follow-up of 39 
      months, the presence of lymphadenopathy in patients with Rai 0-1 stage CLL was 
      the only significant variable for predicting PFS in multivariate analysis (odds 
      ratio [OR] 7, 95% confidence interval [CI] 2.2-22, p = 0.001). When only 
      biological factors were analyzed, CD38 expression (OR 3.2, 95% CI 1.1-9.3, p = 
      0.03) and 17p- (OR 3.5, 95% CI 0.95-13.1, p = 0.05) correlated with worse PFS. A 
      longer follow-up is necessary to analyze the prognostic value of these variables 
      regarding overall survival.
FAU - Oliveira, Ana C
AU  - Oliveira AC
AD  - Servei d'Hematologia Clinica, Institut Catala d'Oncologia, Hospital Duran i 
      Reynals, IDIBELL, Hospitalet, Barcelona, Spain. acoliveira@iconcologia.net
FAU - de la Banda, Esmeralda
AU  - de la Banda E
FAU - Domingo-Domenech, Eva
AU  - Domingo-Domenech E
FAU - Encuentra, Maite
AU  - Encuentra M
FAU - Mercadal, Santiago
AU  - Mercadal S
FAU - Domingo, Alicia
AU  - Domingo A
FAU - Alonso, Esther
AU  - Alonso E
FAU - Espinet, Blanca
AU  - Espinet B
FAU - Grau, Javier
AU  - Grau J
FAU - De Sevilla, Alberto Fernandez
AU  - De Sevilla AF
FAU - Gonzalez-Barca, Eva
AU  - Gonzalez-Barca E
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Cohort Studies
MH  - Cytogenetic Analysis
MH  - Disease-Free Survival
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Immunophenotyping
MH  - Karyotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/mortality/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Analysis
EDAT- 2011/02/18 06:00
MHDA- 2011/06/22 06:00
CRDT- 2011/02/18 06:00
PHST- 2011/02/18 06:00 [entrez]
PHST- 2011/02/18 06:00 [pubmed]
PHST- 2011/06/22 06:00 [medline]
AID - 10.3109/10428194.2010.545463 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Mar;52(3):429-35. doi: 10.3109/10428194.2010.545463.